Algenis SpA
🇨🇱Chile
- Country
- 🇨🇱Chile
- Ownership
- Holding
- Established
- 2002-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.algenis.com
Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy
Phase 1
Recruiting
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: Placebo PSP NEURO SERUM
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Algenis SpA
- Target Recruit Count
- 52
- Registration Number
- NCT05052398
- Locations
- 🇧🇷
Oncoclinicas do Brasil Servicios Medicos SA, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Centro Oncológico do Triângulo S.A., Uberlândia, Minas Gerais, Brazil
🇧🇷Nucleo de Oncologia da Bahia, Salvador, Bahia, Brazil
Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Algenis SpA
- Target Recruit Count
- 30
- Registration Number
- NCT04799041
- Locations
- 🇨🇱
Hospital San José SSMN, Santiago, Metropolitana, Chile
NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Algenis SpA
- Target Recruit Count
- 30
- Registration Number
- NCT03655522
© Copyright 2025. All Rights Reserved by MedPath